Objectives: Early testing of aerosolized sargramostim therapy demonstrated anecdotal clinical responses in patients with metastatic melanoma associated with emergence of systemic antitumor immunity. To improve the clinical and immunologic efficacy of therapy without compromising patient safety, we performed a further dose escalation trial in patients with metastatic melanoma. Methods: We conducted a dose-escalation clinical trial of HLA-A2 ϩ patients with metastatic melanoma to the lung treated with aerosolized granulocyte macrophage colony stimulating factor (GM-CSF) (500 -2000 g/dose, with increments of 250 g/dose/cohort) twice/d on days 1 to 7 and 15 to 21 every 28 days until progression or severe toxicity to find a dose where a majority of patients develop antitumor immunity. Five patients were treated per each dose level. Clinical, immune, and safety parameters were examined. Results: The study accrued 40 patients. Toxicity was acceptable. All doses levels were exhausted without identifying a dose of GM-CSF at which a majority of patients (Ն3 of 5) demonstrated significant up-regulation of antitumor immunity. Three of 16 patients who were tetramer positive for at least one melanoma antigen (eg, MART-1) pretreatment developed an immune response (IR) to different tumor antigens. Two of 9 patients who were tetramer negative to all melanoma antigens pretreatment developed an IR against gp100. The greatest changes in antitumor immunity occurred at the highest dose levels. Conclusions: A dose of aerosolized GM-CSF capable of inducing antitumor immunity in the majority of patients was not reached. All tested doses were well tolerated. The greatest increase in antitumor T cell IRs was achieved at the highest doses of GM-CSF.
T he presence of increased concentrations of sargramostim (granulocyte macrophage colony stimulating factor, GM-CSF) in the tumor/antigen-immune interface appears to result in the generation of effective systemic antitumor immunity and tumor regression. 1, 2 Direct intra/peri tumor injections of recombinant GM-CSF have resulted in melanoma regression. [3] [4] [5] GM-CSF appears to function as a classic immune adjuvant potentiating the immunogenicity of coadministered antigen (vaccine) or endogenous malignancy. We previously reported a phase I trial of aerosolized GM-CSF administered twice/d on days 1 to 7 and 15 to 21 of a 28-day treatment cycle in patients with carcinomas metastatic to the lung. Due to concerns of inflammatory pulmonary/airway toxicities, the doses of GM-CSF tested in this study were very low: 60 g, 120 g and 240 g. The study identified no significant toxicity or impact on pulmonary function tests in the tested dose ranges. 6 Both patients with metastatic melanoma treated on this trial experienced dramatic prolongation of progression free survival. In a separate study, prolongation of progression free survival seemed to be associated with the emergence of melanoma specific cytotoxic T lymphocytes (CTL) in peripheral blood suggesting that the effect of aerosolized GM-CSF may be immune (T cell) mediated. 6, 7 Based on these findings, we hypothesized that aerosol delivery of GM-CSF to the immune/tumor interface in the lung could promote tumor-antigen presentation by tumor associated antigen presenting cells leading to systemic, antimelanoma immunity. Increasing the dose of aerosol GM-CSF further, may lead to more effective autologous antitumor immunization and improved clinical outcomes. Thus, we conducted a step-wise dose escalation clinical trial of HLA-A2 ϩ patients with stage IV melanoma involving the lung (and other sites of metastases) that were treated with aerosolized GM-CSF at doses ranging from 500 g to 2000 g (250 g/dose increments) administered twice/d on days 1 to 7 and 15 to 21 of a 28-day cycle until intolerable toxicity of tumor progression. All patients were evaluated for safety and immunologic efficacy (emergence of melanoma specific T lymphocytes in the peripheral blood). Increased numbers of melanoma specific CTL in peripheral blood would suggest GM-CSF mediated up-regulation of antigen presentation of tumor antigens by the tumor associated antigen-presenting cells leading to systemic antitumor immunity. The method to quantitate emergence of tumor-specific CTL immunity was the tetramer assay for HLA-A2 cognant melanoma differentiation antigen specific peptides (MART-1 27-35 , gp100 209 -217 or tyrosinase 368 -376 ). Herein we present the clinical and laboratory results of this study and discuss these observations on future applications of aerosol GM-CSF therapy.
PATIENTS AND METHODS
The trial enrolled patients who were Ն18 years of age with histologically proven melanoma with radiographic evidence of involvement of the lungs (other sites of metastases in addition to the lung were allowed). Eligibility criteria included: measurable disease, HLA-A2 ϩ status, and forced expiratory volume in 1 second (FEV 1 ) Ն65% of expected and at least 1.5 L. Contradictions to study entry included: unsatisfactory hematologic or blood chemistry profiles, known immune deficiency or ongoing immunosuppressive therapy, Eastern Cooperative Oncology Group performance status of 3 or 4, uncontrolled infection, discontinuation of other cancer therapy Ͻ4 weeks preregistration, central nervous system metastases stable less than 3 months, other malignancies within the last 5 years, and inability to provide informed written consent. All women of childbearing potential had a serum pregnancy test within 7 days of registration (pregnant or lactating women were ineligible). Patients were assigned to the currently open dose level of GM-CSF. Aerosolized GM-CSF was administered twice daily on days 1 to 7 and 15 to 21 of a 28-day cycle. The dose (g) levels under investigation were 500, 750, 1000, 1250, 1500, 1750, and 2000. Aerosolized GM-CSF was self-administered via the Pari-LC nebulizer system (Starnberg, Germany).
Each patient underwent a peripheral blood collection, tumor burden assessment (Response Evaluation Criteria in Solid Tumors), and toxicity evaluation using the National Cancer Institute Common Toxicity Criteria version 2.0 criteria prior to the first 2 cycles of treatment and every other cycle thereafter until treatment discontinuation. Patients who developed moderate dyspnea (grade 3) had to hold further study treatment until symptoms improved to Յ grade 2 and reduce GM-CSF dose by 50% for subsequent treatments. If symptoms did not improve within 2 weeks, treatment was discontinued. Patients who developed a grade 4 dyspnea immediately discontinued treatment.
Study Design
The goal of this dose escalation trial was to find a dose of aerosolized GM-CSF with an acceptable level of toxicity and evidence of increased frequencies of antimelanoma dif-ferentiation antigen specific CTL in at least 3 of 5 patients treated at the given dose level. A dose level was considered to be excessively toxic if Ն2 (or Ն4) of the first 5 (or 10) patients enrolled onto that dose level developed a dose limiting toxicity where dose limiting toxicities included grade 4 hematologic toxicity for more than 7 days or leukocytosis Ͼ50,000 for more than 7 day, any grade 4 pulmonary toxicity, or any Ն grade 3 nonhematologic toxicity. A dose level was considered to have a promising level of immunostimulatory activity if at least 3 of 5 (or 7 of 10) patients treated at that dose level developed an immune response (IR) where an IR was defined as at least a 5-fold increase in frequency of peripheral blood antimelanoma tumor-specific CTL from pretreatment levels within the first 2 cycles of treatment if pretreatment levels were detectable (tetramer frequencies of Ն0.05% of circulating lymphocytes); or detection of antimelanoma CTL IRs within the first 2 cycles of treatment if pretreatment levels were not detectable (Ͻ0.05%). The scheme by which dose escalation was carried out is as follows: 5 patients were entered at a given dose level. If 2 or fewer of these 5 patients developed an IR, then 5 other patients would be enrolled onto the next higher dose level. If 3 or more patients developed an IR, 5 additional patients would be enrolled at the current dose level (total of 10 patients). If 7 or more the 10 patients enrolled on the present dose level develops an IR, enrollment would stop and this would be declared the optimal immunologically effective (IE) dose. If not, 5 other patients would be enrolled on the next higher dose level. Dose escalation would continue until excessive toxicity was encountered, the IE was found, or all 7 dose levels were exhausted.
Sargramostim (GM-CSF, Leukine)
Yeast-derived, glycosylated recombinant GM-CSF (Sargramostim/Leukine; Berlex Labs, Seattle, WA) was provided by the manufacturer. Each vial contained powdered GM-CSF that was reconstituted with sterile or bacteriostatic water for injection, per package insert. Patients were instructed on dose preparation prior to the first cycle of therapy.
Nebulization
Reconstituted GM-CSF (with sterile or bacteriostatic water) was added into a nebulizer bowl of a Pari LC Plus nebulizer connected to a standard air compressor (Pulmo-Aide; DeVilbiss, Glendale Heights, IL) to generate the aerosol mist. When necessary (at the low dose range) Bronchosaline (Blalrex labs, Columbus, OH) was added to the nebulizer bowl to bring up the volume of the GM-CSF to 2 mL (minimal volume for nebulization). Patients inhaled the mist through a valved mouthpiece provided with the nebulizer kit. Aerosol treatments were typically completed in 5 to 15 minutes. The first aerosol GM-CSF treatment was delivered under medical supervision to be certain that maximal aerosol drug delivery is achieved and no immediate toxicity was experienced. All subsequent treatments were self-administered.
Monitoring of Pulmonary Functions
Patients were instructed on the use of telephonic remote spirometry (Asthmalong; Datalog, Stillwater, MN) at the time of nebulization training. The Asthmalog reliably measures forced vital capacity, FEV 1 , peak flow, and forced midexpiratory flow rate 25-75%. The instrument also provides feedback to the patient indicating poor effort or significant change (Ͼ10%) in tested parameters (red/green light on the instrument). Following each set of tests the patients transmitted the information to Datalog and from there the pulmonary function tests were faxed to the Mayo Clinic study data center for review.
Immune Monitoring
IR monitoring was performed using peripheral blood collections obtained prior to immunization and every month while on study. One hundred milliliters of blood were collected into heparinized vacutainer tubes prior to each peptide vaccination. Immediately following collection, peripheral blood mononuclear cells (PBMC) were isolated using a density gradient (Ficol-hypaque; Amersham, Uppsala, Sweden) and frozen in complement-inactivated fetal calf serum with 10% dimethyl sulfoxide (Sigma, St. Louis, MO) and then stored in liquid nitrogen. To minimize interassay variability, all individual patient samples were analyzed at the same time.
Immunophenotyping
Upon completion of sample collection for a given patients, all specimens (PBMCs) were batch analyzed for surface expression of the following CD antigens: CD3, CD4, CD8, CD11c, CD14, CD16, CD20, CD22, CD32, CD44, CD45, CD56, CD62, CD69, HLA-DR, CD80, CD83, CD86, and CD123. The stained cells were washed and fixed with 2% paraformaldehyde. Flow-cytometric analysis was performed using a FACSCalibur flow cytometer and analyzed by Cellquest (Becton-Dickinson, Franklin Lakes, NJ). Interassay variability demonstrates a coefficient of variation of Ͻ10%.
Tetramer Staining
For tetramer analysis of tumor antigen specific CTL, thawed PBMCs were stained with fluorescein isothiocyanate conjugated anti-CD8, PC5 conjugated antihuman CD4, CD14 and CD19 and phycoerythrin labeled HLA-A2 tetramers containing melanoma specific differentiation antigen peptides MART-1 27-35 , gp100 209 -217 or tyrosinase 368 -376 (Beckman Coulter, Fullerton CA). Samples were analyzed by flow cytometry and data was processed using Cellquest software (Becton-Dickinson, Franklin Lakes, NJ). Gates were set on lymphocytes that were CD4, CD14 and CD19 (PC5) negative. Immunophenotyping of lymphocyte subsets (CD3, CD4, CD8, CD20, CD22, and CD14) was performed using fluorescein isothiocyanate or phycoerythrin labeled monoclonal antibodies in accordance to manufacturer's instructions (Becton-Dickinson, Franklin Lakes, NJ). Samples were analyzed by flow cytometry using the same software as described above. Interassay coefficient of variation was consistently Ͻ10% for all tetramers.
RESULTS

Clinical Outcomes
The presented clinical trial enrolled a total of 40 patients. Four patients declined participation prior to receiving treatment. One patient was found to be ineligible due to inadequate FEV 1 levels. A 35-year-old male who entered the study at the 500 g dose level died of rapid progression of disease within 13 days of registration. This patient's data were considered noninformative in terms of the study end point and, thus, not included in the analysis. Another patient was recruited to the 500 g dose level to ensure 5 evaluable patients were treated at this dose level. Patient and tumor characteristics at registration are presented in Table 1 by dose level.
Dose escalation was not terminated due to excessive toxicity and continued through all planned doses without reaching the above defined IE dose. Three patients developed severe toxicities (Ն grade 3) considered "probably," "possibly," or "definitely" related to treatment. Grade 4 dyspnea with grade 3 cough led to the discontinuation of study treatment in one patient after the their first administration of treatment at the 2000 g dose level and in a second patient after 1 cycle of treatment at the 1750 g dose level. Both patients immediately/completely responded to discontinuation of GM-CSF treatment and therapy with nebulized albuterol. Another patient who completed the first cycle of treatment at the 1000 g dose level developed grade 3 fatigue and grade 2 dyspnea but did not continue treatment due to disease progression. Grade 2 toxicities reported as "probably," "possibly," or "definitely" related to treatment included: cough (1 at the 750 g dose), anemia (1 at 750 g), rash (1 at 750 g), constipation (1 at 1500 g), fatigue (1 at 1750 g), dizziness (1 at 2000 g) and nausea (1 at 2000 g). None of the patients exhibited sufficient changes in lung volumes/flow rates to necessitate discontinuation of therapy based on remote spirometry (data not shown).
With regard to clinical benefit, 1 patient enrolled at the 2000 g dose level continues to receive study treatment Ն19.5 months postregistration maintaining a partial tumor response. Five patients demonstrated stable disease for more than 6 months (1 patient each of the following dose levels: 500 g, 750 g, 1500 g, 1750 g and 2000 g) prior to disease progression. Progression free survival and overall survival data, per dose level are presented in Table 2 .
Immune Response Effects of Aerosolized GM-CSF on the Frequency of Melanoma Specific CTL in Peripheral Blood
The primary immunologic objective of this study was to find a dose that would produce an IR in a majority of patients without excessive toxicity (an IE dose). Post-treatment tetramer data were not available for 9 patients due to progression during the first 4 weeks of treatment (6 patients), adverse reaction on day 1 (1 patient), or failure to submit post-treatment blood specimens (2 patients). Of the 13 patients with tetramer data among the 20 patients enrolled on the 1250 g dose or lower, none of 4 patients that were tetramer positive to at least one melanoma specific peptide prior to treatment developed a IR and 2 of 9 patients tetramer negative to the melanoma specific peptides prior to treatment developed an IR to gp100. Of the 12 patients with tetramer data among the 14 patients enrolled at the 1500 g dose and higher, all 12 patients were tetramer positive to at least one melanoma specific peptide prior to treatment but the 3 patients who developed an IR did so against peptides they were tetramer negative prior to treatment (gp100: 2 patients; tyrosinase: 1 patient). In addition, 1 of 4 patients at the 1750 g and 4 of 5 at the 2000 g dose had 2 to 4 fold increases in at least one melanoma specific tetramer positive CTL (MART-1: 1 patient; gp100: 4 patients; tyrosinase: 2 patients) ( Table 3 , Fig. 1 ).
There were immune cell subset immunophenotyping data for 22 of the 34 eligible patients. 2-fold or more increases from pretreatment levels were most often seen in CD3/CD69 expressing activated T cells (6 of 22) . Dendritic cell analysis revealed an increase in the frequency (at least doubling) of the following cell subsets: CD40/DR (6 of 22); CD11c/CD80 (5 of 22); CD11c/CD83 (7 of 22); and CD11c/ CD86 (6 of 22) ( Table 4 ).
Clinical Benefit
In this phase I clinical trial of an otherwise unselected population of patients with metastatic melanoma involving the lung, clinical outcomes data was only descriptive. In terms of clinical benefit, a 57-year-old male with metastases limited to the lung enrolled at the 2000 g dose level developed tetramer positive CTL to tyrosinase but no significant changes in immune cell subsets, continues to receive study treatment Ն19.5 months postregistration maintaining a partial tumor response. Five other males aged 37 to 72 years had stable disease for more than 6 months (1 patient at 500 g; 750 g; 1500 g; 1750 g and 2000 g doses) prior to disease progression. The patient enrolled at the 500 g had multiple sites of metastases including the lung and developed tetramer positive CTL to gp100 and Ն2-fold increases in CD3/CD69 and CD11c/CD83 cell counts. The patient enrolled at the 750 g dose had lung metastases and little 
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Bolded values indicate patients who had a 2-4 fold increase in at least one tetramer positive CTL.
change in any immunologic parameters. The patient enrolled at the 1500 g dose had multiple sites of metastases including the lung and developed tetramer positive CTL to gp100 and little change in immune cell subsets. The patient enrolled at the 1750 g dose had metastases to the lung and little change in tetramer positive CTL but a 3-fold increase in CD11c/ CD83 counts. The patient enrolled at the 2000 g dose had metastases to the lung and had a Ͼ2-fold increase in tetramer positive CTL to gp100 and tyrosinase and in CD11c/CD86 counts. All patients have been followed to death or a minimum of 14 months. The reasons that patients discontinued study treatment included tumor progression (31 patients) and grade 4 dyspnea (2 patients). At last contact, 1 patient was alive without disease progression, 5 were alive with disease progression, and 28 were deceased due to disease progression. Progression-free survival and overall survival are presented by dose level in Table 2 .
With regard to changes in immune (CTL-tetramer) response and associated clinical benefit of therapy, progression-free survival ranged from 4 to Ͼ19.5 months (median: 8.4 months) among the 5 patients who developed an IR; 1 to 15.8 months (median: 2 months) in the 20 patients who did not develop an IR; and 1 to 4.6 months (median: 1 month) among the 9 patients who did not have immune data (Table 2) . lend support to its hypothesized mechanism of action as an inducer of systemic antitumor immunity when administered to the tumor-immune system interface in the lung. The small numbers of patients, limited biospecimen availability for more extensive laboratory study and modest change in measured parameters (tetramers) are only suggestive and not definitive confirmation of effective antitumor immunomodulation (autoimmunization). The suggestion of clinical and immunologic benefits in this phase I study in patients demonstrating at least doubling of the frequencies of melanoma specific CTL lend further support to efforts in the study of aerosol GM-CSF therapy as a means of cancer immunotherapy.
Our first experience with aerosolized GM-CSF suggested that the agent was safe at dose levels of up to 240 g delivered twice per day on days 1 to 7 and 15 to 21 of a 28-day treatment cycle. 8 All patients tolerated therapy very well with no significant toxicity. Interestingly, 2 of the treated patients with metastatic melanoma (stage M1c) demonstrated a partial remission and stabilization of disease progression for over 9 months. Encouraged by these results we embarked on 2 phase II clinical trials further evaluating the safety of the 240 g dose of aerosol GM-CSF for patients with either metastatic melanoma or metastatic renal cell carcinoma involving the lungs (submitted for publication). In both studies, aerosolized GM-CSF was well tolerated. However, clinical benefit was only anecdotal. In the few HLA-A2 ϩ melanoma patients from whom we had available peripheral blood lymphocytes, we were able to identify a trend towards an increase in the frequency of melanoma specific CTL suggesting antitumor autoimmunization. These data were consistent with the observations in our "compassionate use" protocol for patients with a number of different metastatic cancers to the lungs undergoing aerosol GM-CSF therapy. 6 Additionally, data demonstrating alveolar macrophage activation using aerosolized GM-CSF for the treatment of pulmonary alveolar proteinosis further supported the hypothesis of aerosol GM-CSF driven antitumor autoimmunization and gave justification for further dose escalation of aerosolized GM-CSF. 9 Our current study further supports the notion of modulation of immune cell function (antitumor autoimmunization) by aerosolized GM-CSF delivered to metastatic melanoma in the lungs. Although the exact mechanisms remain unclear, the emergence of peripheral blood tumor specific CTL as a result of aerosol GM-CSF therapy, suggests at least an improvement in tumor antigen presentation by tumor-associated antigen presenting cells (eg, alveolar macrophages). The modest systemic emergence of tumor specific CTL was associated with a trend towards improved clinical outcomes as has been suggested previously. 10 Albeit limited in scope, our current study demonstrates the safety of aerosol GM-CSF delivery at doses up to 200 g/treatment and further illustrates the potential of induction of antitumor autoimmunization with the emergence of peripheral blood tumor specific CTL. To fully understand the clinical and immunologic benefits of this approach to therapy, dose escalation to a maximally tolerated dose is indicated. We were unable to extend the dose escalation schema of the current study due to the prohibitive cost of further increases in GM-CSF dose resulting from the poor efficiency of the used aerosol delivery apparatus (Pari LC Plus). We are currently exploring alternate, more efficient means of aerosol drug delivery.
The current study demonstrates the plausibility of antitumor autoimmunization using aerosolized GM-CSF therapy for patients with metastatic melanoma to the lungs. The potential clinical benefits/applications of fully defining an effective/reproducible aerosol GM-CSF autoimmunization treatment protocol are not insignificant. Such efforts may complement ongoing T-cell immunomodulatory strategies in cancer therapy (eg, anti-CTLA4). Utilization of aerosol GM-CSF as "adjuvant" treatment following tumor-ablative procedures (eg, local radiation or cryoablation) may lead to greater antitumor autoimmunization efficacy (ie, disruption of the immunosuppressive tumor microenvironment with local/regional release of antigens). Likewise, the ability to modulate pulmonary antigen presenting cells with aerosolized GM-CSF raises the possibility of aerosol GM-CSF as an immune adjuvant to aerosolized vaccines. Simultaneous aerosol delivery of GM-CSF with vaccine antigens may result in the development of both systemic and mucosal immunity, not achievable by other modes of immunization. [11] [12] [13] [14] [15] This may be particularly relevant following the success of nasal mucosal immunization for influenza. 16 -23 In summary, the presented data from our phase I clinical trial illustrates the safety of aerosol GM-CSF therapy and suggests a possible clinical and immunologic benefit of aerosolized GM-CSF therapy in patients with metastatic melanoma to the lungs. The data also suggest that further dose escalation (or prolonged treatment schedule) to maximally tolerated doses of GM-CSF may be warranted in an effort to identify a more clinically and IE dose that could be considered for further therapeutic efficacy, phase II testing.
